Targeting CD13/Aminopeptidase N as a Novel Therapeutic Approach for Scleroderma Fibrosis

Area of Science:

• Immunology and Rheumatology
• Dermatology
• Molecular Biology

Background:

• Systemic sclerosis (SSc) is an autoimmune disease with limited treatment options.
• The sCD13-B1R signaling pathway is implicated in pro-inflammatory and pro-fibrotic responses.
• Understanding SSc pathogenesis is crucial for developing effective therapies.

Purpose of the Study:

• To investigate the antifibrotic potential of targeting the sCD13-B1R axis in SSc.
• To explore the role of sCD13 and B1R in SSc skin fibrosis.

Main Methods:

• Examined CD13, B1R, and MMP14 expression in SSc skin and fibroblasts.
• Assessed the efficacy of B1R antagonists in vitro and in vivo models of SSc.
• Utilized gene expression analysis, cell signaling assays, and mouse models of bleomycin-induced fibrosis.

Main Results:

• Elevated CD13, B1R, and MMP14 gene expression was observed in SSc skin.
• sCD13 and TGFβ promoted fibrotic responses in SSc fibroblasts, which were blocked by B1R antagonists.
• Mice lacking CD13 or B1R, and those treated with B1R inhibitors, showed reduced skin fibrosis and inflammation.

Conclusions:

• The sCD13-B1R axis plays a significant role in SSc skin fibrosis.
• Targeting the sCD13-B1R signaling pathway represents a novel and promising therapeutic strategy for SSc.